Cipla Share Price Live Updates: Cipla's Market Performance Update
The live blog provides real-time updates on Cipla's stock performance, with the latest data showing shares trading at Rs 1306.5, a market capitalization of Rs 105536.8 crore, and a P/E ratio of 23.21 as of April 29, 2026.
Apr 29 2026 08:04:00
Stock Market Crash LIVE Updates: Nifty above 23,900; Hind Zinc profit up 68%
Cipla's stock recorded a gain of 5.56%, closing at ₹1,305.00, as observed in live market statistics.
Apr 24 2026 14:04:00
Sensex Today | Stock Market LIVE Updates: Nifty extends losses to 290 points; UTI AMC down 10%
Indian benchmark indices experienced broad-based gains, with the Nifty IT Index leading the rally due to easing crude prices and global cues, specifically hopes of progress in US-Iran negotiations. Pharma stocks, including Cipla, also saw gains, attributed to a weak rupee benefiting export-oriented companies. The overall market sentiment was influenced by geopolitical developments and upcoming corporate earnings.
Apr 24 2026 12:04:00
Sensex Today | Stock Market LIVE Updates: Nifty IT extends losses to 1,200 points; LTM, Coforge top losers
Indian equity markets saw a decline, with the Nifty and Sensex ending lower. Among the top losers were M&M, Apollo Hospitals, Coal India, Cipla, SBI Life, Ultratech Cement, and Maruti Suzuki, with Cipla shares reportedly down up to 1.2 percent. The broader market movement was influenced by weak global cues and tariff uncertainties.
Apr 24 2026 11:04:00
Cipla shares under pressure after USFDA import alert on key supplier
Shares of pharmaceutical major Cipla experienced pressure following an import alert issued by the USFDA against W S Labs, a key supplier to the company. This regulatory action on a supplier raises concerns regarding potential disruptions to Cipla's supply chain.
Apr 24 2026 10:04:00
Cipla among 6 stocks flashing bullish signals, hinting at a possible uptrend
Cipla is among six stocks from the Nifty500 that appeared on a 'White Marubozu' bullish scanner on April 23, 2026, indicating strong buying pressure and suggesting a potential uptrend.
Apr 24 2026 08:04:00
Cipla jumps nearly 5% after USFDA nod for generic Ventolin inhaler
Cipla Ltd. received final approval from the U.S. Food and Drug Administration (USFDA) for its Albuterol Sulfate Inhalation Aerosol, a generic equivalent to Ventolin HFA Inhalation Aerosol. This product targets a U.S. market with sales of close to $2.8 billion, strengthening Cipla's presence in the U.S. respiratory segment.
Apr 23 2026 10:04:00
Cipla Limited
Cipla's Goa manufacturing facility underwent a routine USFDA inspection from April 6-17, 2026. The inspection resulted in two observations, which Cipla is committed to addressing within the stipulated time.
Apr 17 2026 16:04:00
Cipla Limited
Cipla board will convene on May 13, 2026, to approve its audited annual financial results for FY26. The meeting will also include a recommendation for a final dividend.
Mar 31 2026 19:03:00
Cipla Ltd - 500087 - Board Meeting Intimation for The Quarter And Year Ended 31St March, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla's Board of Directors will meet on May 13, 2026, to consider and approve the audited financial results for Q4 and the full year ended March 31, 2026. The agenda also includes the recommendation of a final dividend for FY26.
Mar 31 2026 19:03:00
Read More